摘要
目的:探讨安罗替尼维持治疗应用非小细胞肺癌的临床效果及安全性研究。方法:选取2016-12~2018-06在我院治疗的64例非小细胞肺癌病人为研究对象,随机分为对照组32例和观察组32例,对照组病人定期复查,观察组病人采用安罗替尼维持治疗,观察参与本次研究病人的疾病缓解率、疾病控制率、生存期情况、KPS评分以及不良反应的发生率。结果:观察组病人的疾病缓解率、疾病控制率明显高于对照组(P<0.05);观察组病人中位生存期以及总生存期与对照组相比均明显升高,差异具有统计学意义(P<0.05);治疗前病人血清KPS评分无显著差异,治疗6周后观察组病人的KPS评分与对照组相比明显改善(P<0.05);两组病人高血压、出血等不良反应的发生率无统计学意义(P>0.05)。结论:将安罗替尼维持治疗应用于非小细胞肺癌病人,可提高治疗效果,且安全性高,值得在临床进行推荐。
Objective:To study the clinical effect and safety of the maintenance treatment of non-small cell lung cancer with arotinib.Methods:64 patients with NSCLC who were treated in our hospital from December 2016 to June 2018 were randomly divided into control group(32 cases)and observation group(32 cases).The patients in the control group were reexamined regularly.The patients in the observation group were treated with arotinib maintenance therapy.The disease remission rate,disease control rate,quality of life(KPS score)and oncology related indexes were observed The level of neuron specific enolase(NSE)in serum and the incidence of adverse reactions in skin system and digestive system.Results:The disease remission rate and disease control rate of the observation group were significantly higher than those of the control group(P<0.05);the median survival time and total survival time of the observation group were significantly higher than those of the control group(P<0.05);After 6 weeks of treatment,the KPS score of observation group was significantly improved compared with that of control group(P<0.05);the incidence of adverse reactions such as hypertension and bleeding in two groups was not statistically significant(P>0.05).Conclusion:the application of arotinib maintenance therapy in non-small cell lung cancer patients can improve the therapeutic effect and has high safety,which is worthy of clinical recommendation.
作者
樊燕青
郝琳
赵志霞
张志聪
彭志锋
张继红
孟健
FAN Yan-qing;HAO Lin;ZHAO Zhi-xia(Internal Medicine,The Third Affiliated Hospital of Kunming Medical University,Yunnan Cancer Hospital,Kunming 650500 China)
出处
《内蒙古医科大学学报》
2021年第1期5-8,30,共5页
Journal of Inner Mongolia Medical University
基金
大同市科技局重点研发(社会发展)项目(2020086)。
作者简介
樊燕青(1983-),女,昆明医科大学第三附属医院,大同市第二人民医院急诊科主治医师。
